Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -42.68
- Piotroski Score 0.00
- Grade Buy
- Symbol (WINT)
- Company Windtree Therapeutics, Inc.
- Price $0.49
- Changes Percentage (-8.11%)
- Change -$0.04
- Day Low $0.47
- Day High $0.53
- Year High $22.32
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $13.31
- Trailing P/E Ratio 0.24
- Forward P/E Ratio 0.24
- P/E Growth 0.24
- Net Income $-20,291,000
Income Statement
Quarterly
Annual
Latest News of WINT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Winter weather warnings for five states as 18 inches of snow to hit
Winter storm warnings and advisories issued by the NWS are affecting multiple U.S. states, with severe conditions expected on the West Coast and parts of the Northeast. Snow, freezing rain, and bitter...
By Newsweek | 21 hours ago -
Tire chain costs hit all-time high Northern California gears up for another winter storm
Caltrans is preparing for upcoming snowfall after a recent weather system passed through Placer County. The cost of tire chains is at an all-time high, with a pack now around $100. Workers are stockin...
By CBS News | 23 hours ago -
Blue Jays Projection Predicts Multiple Stars To Toronto This Winter
The Toronto Blue Jays are eyeing an exciting free-agency period, aiming to sign Juan Soto for a massive contract to boost their offensive lineup. Rotman's dream lineup for Opening Day 2025 includes So...
By Newsweek | 1 day ago
